Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 21, 2020 09:15 ET | Source: Ritter Pharmaceuticals, Inc.

Ritter Pharmaceuticals, Inc. and Qualigen, Inc. Announce Merger Agreement

Transaction to Create a Nasdaq-listed Biotechnology Company Focused on Advancing Qualigen’s Cancer and Infectious Disease Therapeutic Development Programs LOS ANGELES, Jan. 21, 2020 (GLOBE...
November 13, 2019 19:35 ET | Source: Ritter Pharmaceuticals, Inc.

Ritter Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2019 and Provides Business Update

LOS ANGELES, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of therapeutic products that modulate the gut...
October 07, 2019 09:00 ET | Source: Ritter Pharmaceuticals, Inc.

Ritter Pharmaceuticals Engages Financial Advisor to Explore Strategic Alternatives

LOS ANGELES, Oct. 07, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that...
September 12, 2019 16:15 ET | Source: Ritter Pharmaceuticals, Inc.

Ritter Pharmaceuticals Reports Top-Line Results from its Liberatus Phase 3 Trial of RP-G28 for Lactose Intolerance

LOS ANGELES, Sept. 12, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that...
August 14, 2019 17:11 ET | Source: Ritter Pharmaceuticals, Inc.

Ritter Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2019 and Provides a Corporate Update

LOS ANGELES, Aug. 14, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate...
August 13, 2019 09:15 ET | Source: Ritter Pharmaceuticals, Inc.

Ritter Pharmaceuticals Appoints Esteemed Gastroenterologist Anthony J. Lembo, M.D. to its Medical Advisory Board

LOS ANGELES, Aug. 13, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate...
August 08, 2019 14:16 ET | Source: Ritter Pharmaceuticals, Inc.

Ritter Pharmaceuticals Provides Highlights from Lactose Intolerance Market Research Call

Market research indicates an unmet need for better lactose intolerance treatments and interest from both patients and physicians in the RP-G28 drug profile LOS ANGELES, Aug. 08, 2019 (GLOBE...
July 31, 2019 09:00 ET | Source: Ritter Pharmaceuticals, Inc.

Ritter Pharmaceuticals Hosts Conference Call on August 7, 2019 to Highlight Recent Lactose Intolerance Market Research Findings

Daniel P. Lundberg, Consultant to Ritter Pharmaceuticals and former Senior VP of Marketing at Salix Pharmaceuticals to address market opportunity for Phase 3, lactose intolerance drug candidate RP-G28...
July 11, 2019 17:28 ET | Source: Ritter Pharmaceuticals, Inc.

Ritter Pharmaceuticals Regains Compliance with Nasdaq’s Minimum Bid Price Requirement

Ritter Shares Will Continue to Trade on the Nasdaq Capital Market LOS ANGELES, July 11, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the...
July 02, 2019 09:00 ET | Source: Ritter Pharmaceuticals, Inc.

Ritter Pharmaceuticals Announces Last Patient Last Visit in its Phase 3 “Liberatus” Clinical Trial of RP-G28 for Lactose Intolerance

Top-line Data Readout Remains on Track for early Q4 2019 LOS ANGELES, July 02, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a...